U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    MIR510 microRNA 510 [ Homo sapiens (human) ]

    Gene ID: 574515, updated on 4-Jan-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Circular RNA sirtuin-1 restrains the malignant phenotype of non-small cell lung cancer cells via the microRNA-510-5p/SMAD family member 7 axis.

    Circular RNA sirtuin-1 restrains the malignant phenotype of non-small cell lung cancer cells via the microRNA-510-5p/SMAD family member 7 axis.
    Zhao Z, Zhang H, Zhang F, Ji Y, Peng Y, Wang F, Zhao L.

    01/3/2024
    MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth.

    MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth.
    King B, Krisanits BA, Guo QJ, Blake B, Nogueira LM, Jolly G, Satterwhite A, Turner DP, Hoffman S, Evans-Knowell A, Findlay VJ., Free PMC Article

    10/13/2023
    Long Non-Coding RNA Small Nucleolar RNA Host Gene 4 Induced by Transcription Factor SP1 Promoted the Progression of Nasopharyngeal Carcinoma Through Modulating microRNA-510-5p/Centromere Protein F Axis.

    Long Non-Coding RNA Small Nucleolar RNA Host Gene 4 Induced by Transcription Factor SP1 Promoted the Progression of Nasopharyngeal Carcinoma Through Modulating microRNA-510-5p/Centromere Protein F Axis.
    Zhou S, Cao C, Hu J.

    09/25/2023
    Novel circular RNA circSLIT2 facilitates the aerobic glycolysis of pancreatic ductal adenocarcinoma via miR-510-5p/c-Myc/LDHA axis.

    Novel circular RNA circSLIT2 facilitates the aerobic glycolysis of pancreatic ductal adenocarcinoma via miR-510-5p/c-Myc/LDHA axis.
    Guan H, Luo W, Liu Y, Li M., Free PMC Article

    09/25/2021
    These results indicated that LINC00702 modulated the expression of PTEN gene by acting as a ceRNA for miR-510 in non-small cell lung cancer.

    LINC00702 suppresses proliferation and invasion in non-small cell lung cancer through regulating miR-510/PTEN axis.
    Yu W, Li D, Ding X, Sun Y, Liu Y, Cong J, Yang J, Sun J, Ning X, Wang H, Xu T., Free PMC Article

    05/30/2020
    These results showed that miR-510 acted as an oncogenic miRNA in NSCLC, partly by targeting SRCIN1, suggesting that miR-510 can be a potential approach for the treatment of patients with malignant lung cancer.

    MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
    Wu W, He L, Huang Y, Hou L, Zhang W, Zhang L, Wu C., Free PMC Article

    01/11/2020
    Our results revealed that miR-510 was upregulated in blood samples from hypertension patients, compared with controls. Methylation analyses corroborated the miR-510 upregulation in patient samples.

    Expression and methylation of circulating microRNA-510 in essential hypertension.
    Krishnan R, Mani P, Sivakumar P, Gopinath V, Sekar D.

    09/30/2017
    MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.

    MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.
    Guo QJ, Mills JN, Bandurraga SG, Nogueira LM, Mason NJ, Camp ER, Larue AC, Turner DP, Findlay VJ., Free PMC Article

    12/20/2014
    Data show significantly increased expression of miRNA-510 and decreased expression of both miRNA-342 and miRNA-191 in Tregs of diabetic patients.

    microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients.
    Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J, Michalek J.

    01/21/2010
    The binding site for miR-510 is solely located in the 3' UTR of the HTR3E gene. No predicted binding site for miR-510 exists in the 3' UTR of HTR3A.

    First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome.
    Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, Gassler N, Fischer C, Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtmann M, van der Voort I, Wisser AS, Berg T, Rappold G, Niesler B.

    01/21/2010
    firstprevious page of 1 nextlast